• E-mail page
• Print page
• Text size   

• CRESTOR^® (rosuvastatin calcium) - Home Page
• About CRESTOR
  • Indications
  • Safety and Tolerability
  • Dosing and Titration
  • Pharmacokinetics
• Clinical Experience
  • Lowering LDL-C: Starting Therapy Comparative Data
  • Lowering LDL-C: Switching Therapy Comparative Data
  • Raising HDL-C: Comparative Data
  • Slowing Atherosclerosis Progression
  • Use in Patients With Diabetes
  • Use in Specific Populations: Comparative Data
  • Safety
• Patient Support
  • Order Patient Education Materials Now
  • Interactive Tools
  • Patient Support Programs
  • Money-Saving Offers
  • Consumer Awareness Campaign
• Resources and Tools
  • CRESTOR Formulary Tool
  • Journal Reprints
  • The AstraZeneca Medical Information for Health Care Professionals Web Site
  • Web Resources
• Get Updates About CRESTOR
• E-mail This Page
• Site Map
• Privacy Statement
• Legal Information
• Contact Us

CRESTOR is indicated^#

• As an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia
• As an adjunct to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels
• CRESTOR is not indicated to reduce cardiovascular morbidity and mortality

CRESTOR is contraindicated^#

• In patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers

Important safety information about CRESTOR^#

• Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg)
• CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir
• Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever
• CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose
• It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (eg, semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume substantial quantities of alcohol
• In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%)^‡‡